We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) closed at $168.10 in the latest trading session, marking a +1.22% move from the prior day. This change lagged the S&P 500's 1.49% gain on the day. On the other hand, the Dow registered a gain of 0.71%, and the technology-centric Nasdaq increased by 2.26%.
The stock of pharmaceutical has risen by 0.06% in the past month, leading the Medical sector's loss of 1.14% and undershooting the S&P 500's gain of 0.1%.
The investment community will be paying close attention to the earnings performance of Astrazeneca in its upcoming release. The company is expected to report EPS of $2.17, down 8.82% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $16.07 billion, up 5.82% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $9.34 per share and a revenue of $63.19 billion, demonstrating changes of +1.97% and +7.58%, respectively, from the preceding year.
Any recent changes to analyst estimates for Astrazeneca should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 8.49% fall in the Zacks Consensus EPS estimate. Astrazeneca presently features a Zacks Rank of #5 (Strong Sell).
With respect to valuation, Astrazeneca is currently being traded at a Forward P/E ratio of 17.77. This signifies a discount in comparison to the average Forward P/E of 23.38 for its industry.
Also, we should mention that AZN has a PEG ratio of 1.41. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.93 at the close of the market yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 168, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note
Astrazeneca (AZN - Free Report) closed at $168.10 in the latest trading session, marking a +1.22% move from the prior day. This change lagged the S&P 500's 1.49% gain on the day. On the other hand, the Dow registered a gain of 0.71%, and the technology-centric Nasdaq increased by 2.26%.
The stock of pharmaceutical has risen by 0.06% in the past month, leading the Medical sector's loss of 1.14% and undershooting the S&P 500's gain of 0.1%.
The investment community will be paying close attention to the earnings performance of Astrazeneca in its upcoming release. The company is expected to report EPS of $2.17, down 8.82% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $16.07 billion, up 5.82% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $9.34 per share and a revenue of $63.19 billion, demonstrating changes of +1.97% and +7.58%, respectively, from the preceding year.
Any recent changes to analyst estimates for Astrazeneca should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 8.49% fall in the Zacks Consensus EPS estimate. Astrazeneca presently features a Zacks Rank of #5 (Strong Sell).
With respect to valuation, Astrazeneca is currently being traded at a Forward P/E ratio of 17.77. This signifies a discount in comparison to the average Forward P/E of 23.38 for its industry.
Also, we should mention that AZN has a PEG ratio of 1.41. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.93 at the close of the market yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 168, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.